Experimental and Clinical Psychopharmacology®

ISSN: 1064-1297
eISSN: 1936-2293
Published: bimonthly, beginning in February
ISI Impact Factor: 2.626
Psychology - Clinical : 27 of 111

Experimental and Clinical Psychopharmacology ® publishes advances in translational and interdisciplinary research on psychopharmacology and drug abuse. The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, brain imaging, genetics, neuroendocrinology, neuroscience, and pharmacology.

One goal of the journal is to encourage increased attention to biologic factors that may influence both the pharmacodynamic and the pharmacokinetic effects of drugs. Recent research has shown the importance of examining the effects of sex and menstrual/estrous cycle phase on the effects of abused drugs, as well as responses to medications for the treatment of drug abuse and the alleviation of pain.

The journal publishes original reports on the development and evaluation of new pharmacotherapies, the influence of genetics and hormones on responses to abused drugs and treatment medications, the pharmacological management of pain, and brain imaging studies of the neural correlates of drug effects.

The journal will focus on clinical laboratory studies and controlled clinical medication trials as well as basic preclinical experiments on psychopharmacology and drug abuse.

The journal also will include comprehensive and integrative reviews of advances in research on psychopharmacology. These reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches.

Each year, the journal will recognize young investigators who are recipients of the Young Psychopharmacologist Award or the Best Dissertation Award, as well as midcareer and senior scientists who receive the Brady–Schuster Award from APA Division 28, Psychopharmacology and Substance Abuse. Awardees will be invited to submit a review paper based on their award-winning research.

The journal may occasionally publish innovations in psychopharmacology that report a novel method, measure, or result. Commentary on the nature and implications of the innovation may be invited.

The overall goal is to provide a forum for innovative clinical and preclinical research that advances our understanding of the behavioral and biological determinants of the effects of drugs.

Experimental and Clinical Psychopharmacology® is a registered trademark of American Psychological Association
Editorial Board


Suzette M. Evans
Columbia University Medical Center and the New York State Psychiatric Institute

Consulting Editors

Ashley Acheson
Neurobehavioral Research Laboratory and Clinic (NRLC), The University of Texas Health Science Center at San Antonio

Justin J. Anker
University of Minnesota

Robert L. Balster
Center for the Study of Tobacco Products, Virginia Commonwealth University

Warren K. Bickel (Editor Emeritus)
Addiction Recovery Research Center, Virginia Tech Carilion Research Institute

Thomas H. Brandon
Health Outcomes & Behavior, Moffitt Cancer Center

Cynthia A. Conklin
University of Pittsburgh

Donald M. Dougherty
University of Texas Health Science Center at San Antonio

Stephen T. Higgins
University of Vermont

Leonard L. Howell
Emory University

Andrew J. Jones
University of Liverpool

Hendree E. Jones
University of North Carolina School of Medicine

Marc J. Kaufman
McLean Imaging Center, McLean Hospital

Mikhail N. Koffarnus
Virginia Polytechnic Institute and State University

Henry R. Kranzler
Center for Studies of Addiction, University of Pennsylvania

Carl W. Lejuez
University of Maryland

Anthony Liguori
Lakeland College

John E. McGeary
Brown University Medical School, Rhode Island Hospital, and Providence VA Medical Center

S. Stevens Negus
Virginia Commonwealth University

Patrick D. Quinn
Indiana University

Stephanie C. Reed
New York State Psychiatric Institute

Brady Reynolds
University of Kentucky

Mark A. Smith
Davidson College

Roger D. Spealman
New England Primate Research Center, Harvard Medical School

Dace S. Svikis
Virginia Commonwealth University

Sharon L. Walsh
University of Kentucky

Cora Lee Wetherington
National Institute on Drug Abuse

Richard Yi
University of Maryland

Abstracting & Indexing

Abstracting and indexing services providing coverage of Experimental and Clinical Psychopharmacology®

  • Addiction Abstracts
  • Abstracts of Mycology
  • Biological Abstracts
  • BIOSIS Previews
  • Chemical Abstracts
  • Excerpta Medica. Abstract Journals
  • Journals@Ovid
  • Neuroscience Citation Index
  • Ovid
  • PsycINFO
  • PubMed
  • Reactions Weekly
  • Science Citation Index
  • Social Sciences Citation Index
  • SwetsWise All Titles
Instructions to Authors

Prior to submission, please carefully read and follow the submission guidelines detailed below. Manuscripts that do not conform to the submission guidelines may be returned without review.


Beginning April 2012, the completion of the Author Checklist (PDF, 36KB) that signifies that authors have read this material and agree to adhere to the guidelines is now required. The checklist should follow the cover letter as part of the submission, or it can also be inserted into the manuscript file itself. Submissions lacking the checklist will be returned to the author as incomplete.

Submit manuscripts electronically through the Manuscript Submission Portal (.pdf format).

Manuscript Submission Portal Entrance

Submissions mailed to the editorial office will not be processed.

General correspondence may be directed to:

Suzette M. Evans, PhD, Editor
The New York State Psychiatric Institute and Columbia University College of Physicians & Surgeons
1051 Riverside Drive
Unit 66, Room 3704
New York, NY, 10032

In addition to complete addresses and phone numbers, please supply email addresses and fax numbers for all authors for potential use by the editorial office and, later, by the production office.

Experimental and Clinical Psychopharmacology® publishes three types of manuscripts:

  • original research reports
  • reviews of the literature
  • innovations in psychopharmacology

Innovations in Psychopharmacology is published occasionally to report a novel method, a novel result, or a novel measure. Commentary on the nature and implications of the innovation may be invited.

In recognition of the reality that institutional spam filters may capture files from the APA and the Journals Back Office, please take the following steps to facilitate communication with our editorial office:

  • Provide an alternative email address which we can use to contact you in the event of technical difficulties with email communication using your primary address
  • Add "apa.org" to your list of "safe" addresses and consider asking your IT administrators to add it to their "white list"
  • Contact Megan Mabe-Stanberry if you do not receive confirmation of your submission within three business days or an editorial decision letter within three months

Cover Letter

To help with the review process, authors should provide up to five scientists who are qualified to review their manuscript without bias or conflict of interest. Please provide prospective reviewers' names, affiliations, academic rank, email address, complete mailing address, and phone number in the cover letter. Submissions lacking reviewer recommendations will be returned to the author as incomplete.

Title Page

Include the corresponding author's email and mailing addresses; phone and fax numbers; and the names, degrees, and affiliations of all authors, as well as the number of figures and tables in the manuscript.

Abstract and Keywords

All manuscripts must include an abstract containing a maximum of 250 words typed on a separate page. After the abstract, please supply up to five keywords or brief phrases.

Disclosures and Acknowledgments

Authors are now required to provide a Disclosures and Acknowledgements section. This section should be included on a separate page after the Abstract, as separate paragraphs for each of the four points (do not number or provide headers). This section will be automatically incorporated into the online submission system and if the paper is accepted, will appear in the published journal article.

First, authors should state all sources of financial support for the conduct of the research (e.g., This research was supported by NIDA grant X). If the funding source was involved in any other aspects of the research (e.g., study design, analysis, interpretation, writing), then clearly state the role. If the funding source had no other involvement other than financial support, then simply state that the funding source had no other role other than financial support.

Second, a contributors statement should be included indicating that all authors contributed in a significant way to the manuscript and that all authors have read and approved the final manuscript.

Third, all authors are expected to provide a conflict of interest statement disclosing any real or potential conflict(s) of interest, including financial, personal, or other relationships with other organizations or pharmaceutical/biomedical companies that may inappropriately impact or influence the research and interpretation of the findings. If there are no conflicts of interest, this should be clearly stated.

Fourth, authors are encouraged to acknowledge the assistance or contribution of others in the endeavors of the research.

Review Policy

Authors may suggest up to five scientists who are qualified to review their manuscript without bias or conflict of interest. Send prospective reviewers' names, affiliations, academic rank, email address, complete mailing address, and phone number in your cover letter.

Manuscript Preparation

Prepare manuscripts according to the Publication Manual of the American Psychological Association (6th edition). Manuscripts may be copyedited for bias-free language (see Chapter 3 of the Publication Manual).

Review APA's Checklist for Manuscript Submission before submitting your article.

If your manuscript was mask reviewed, please ensure that the final version for production includes a byline and full author note for typesetting.

Double-space all copy. Other formatting instructions, as well as instructions on preparing tables, figures, references, metrics, and abstracts, appear in the Manual.

Below are additional instructions regarding the preparation of display equations, computer code, and tables.

Display Equations

We strongly encourage you to use MathType (third-party software) or Equation Editor 3.0 (built into pre-2007 versions of Word) to construct your equations, rather than the equation support that is built into Word 2007 and Word 2010. Equations composed with the built-in Word 2007/Word 2010 equation support are converted to low-resolution graphics when they enter the production process and must be rekeyed by the typesetter, which may introduce errors.

To construct your equations with MathType or Equation Editor 3.0:

  • Go to the Text section of the Insert tab and select Object.
  • Select MathType or Equation Editor 3.0 in the drop-down menu.

If you have an equation that has already been produced using Microsoft Word 2007 or 2010 and you have access to the full version of MathType 6.5 or later, you can convert this equation to MathType by clicking on MathType Insert Equation. Copy the equation from Microsoft Word and paste it into the MathType box. Verify that your equation is correct, click File, and then click Update. Your equation has now been inserted into your Word file as a MathType Equation.

Use Equation Editor 3.0 or MathType only for equations or for formulas that cannot be produced as Word text using the Times or Symbol font.

Computer Code

Because altering computer code in any way (e.g., indents, line spacing, line breaks, page breaks) during the typesetting process could alter its meaning, we treat computer code differently from the rest of your article in our production process. To that end, we request separate files for computer code.

In Online Supplemental Material
We request that runnable source code be included as supplemental material to the article. For more information, visit Supplementing Your Article With Online Material.

In the Text of the Article
If you would like to include code in the text of your published manuscript, please submit a separate file with your code exactly as you want it to appear, using Courier New font with a type size of 8 points. We will make an image of each segment of code in your article that exceeds 40 characters in length. (Shorter snippets of code that appear in text will be typeset in Courier New and run in with the rest of the text.) If an appendix contains a mix of code and explanatory text, please submit a file that contains the entire appendix, with the code keyed in 8-point Courier New.


Use Word's Insert Table function when you create tables. Using spaces or tabs in your table will create problems when the table is typeset and may result in errors.

Submitting Supplemental Materials

APA can place supplemental materials online, available via the published article in the PsycARTICLES® database. Please see Supplementing Your Article With Online Material for more details.


List references in alphabetical order. Each listed reference should be cited in text, and each text citation should be listed in the References section.

Examples of basic reference formats:

  • Journal Article:
    Hughes, G., Desantis, A., & Waszak, F. (2013). Mechanisms of intentional binding and sensory attenuation: The role of temporal prediction, temporal control, identity prediction, and motor prediction. Psychological Bulletin, 139, 133–151. http://dx.doi.org/10.1037/a0028566
  • Authored Book:
    Rogers, T. T., & McClelland, J. L. (2004). Semantic cognition: A parallel distributed processing approach. Cambridge, MA: MIT Press.
  • Chapter in an Edited Book:
    Gill, M. J., & Sypher, B. D. (2009). Workplace incivility and organizational trust. In P. Lutgen-Sandvik & B. D. Sypher (Eds.), Destructive organizational communication: Processes, consequences, and constructive ways of organizing (pp. 53–73). New York, NY: Taylor & Francis.


Graphics files are welcome if supplied as Tiff or EPS files. Multipanel figures (i.e., figures with parts labeled a, b, c, d, etc.) should be assembled into one file.

The minimum line weight for line art is 0.5 point for optimal printing.

For more information about acceptable resolutions, fonts, sizing, and other figure issues, please see the general guidelines.

When possible, please place symbol legends below the figure instead of to the side.

APA offers authors the option to publish their figures online in color without the costs associated with print publication of color figures.

The same caption will appear on both the online (color) and print (black and white) versions. To ensure that the figure can be understood in both formats, authors should add alternative wording (e.g., "the red (dark gray) bars represent") as needed.

For authors who prefer their figures to be published in color both in print and online, original color figures can be printed in color at the editor's and publisher's discretion provided the author agrees to pay:

  • $900 for one figure
  • An additional $600 for the second figure
  • An additional $450 for each subsequent figure


Authors of accepted papers must obtain and provide to the editor on final acceptance all necessary permissions to reproduce in print and electronic form any copyrighted work, including test materials (or portions thereof), photographs, and other graphic images (including those used as stimuli in experiments).

On advice of counsel, APA may decline to publish any image whose copyright status is unknown.

Publication Policies

APA policy prohibits an author from submitting the same manuscript for concurrent consideration by two or more publications.

See also APA Journals® Internet Posting Guidelines.

APA requires authors to reveal any possible conflict of interest in the conduct and reporting of research (e.g., financial interests in a test or procedure, funding by pharmaceutical companies for drug research).

Authors of accepted manuscripts are required to transfer the copyright to APA.

Ethical Principles

It is a violation of APA Ethical Principles to publish "as original data, data that have been previously published" (Standard 8.13).

In addition, APA Ethical Principles specify that "after research results are published, psychologists do not withhold the data on which their conclusions are based from other competent professionals who seek to verify the substantive claims through reanalysis and who intend to use such data only for that purpose, provided that the confidentiality of the participants can be protected and unless legal rights concerning proprietary data preclude their release" (Standard 8.14).

APA expects authors to adhere to these standards. Specifically, APA expects authors to have their data available throughout the editorial review process and for at least 5 years after the date of publication.

Authors are required to state in writing that they have complied with APA ethical standards in the treatment of their sample, human or animal, or to describe the details of treatment.

The APA Ethics Office provides the full Ethical Principles of Psychologists and Code of Conduct electronically on its website in HTML, PDF, and Word format. You may also request a copy by emailing or calling the APA Ethics Office (202-336-5930). You may also read "Ethical Principles," December 1992, American Psychologist, Vol. 47, pp. 1597–1611.

Other Information

Special Issues
  • Psychopharmacology of Attention

    Special issue of the APA journal Experimental and Clinical Psychopharmacology, Vol. 21, No. 5, October 2013. The articles not only provide novel data on the relationships among attention, alcohol use, and other drug use, but also offer new insights that could inform development of potential pharmacotherapies for ADHD.

  • Perspectives on Prescription Drug Abuse and Relief of Pain

    Special issue of the APA journal Experimental and Clinical Psychopharmacology, Vol. 16, No. 5, October 2008. Includes articles about chronic pain and drug self-administration; evaluation of prescription opioids; sex differences in effects of opioids; strategies to optimize pain management while minimizing drug abuse; opioid misuse and chronic pain treatment; and treatment of addiction to prescription opioids.

  • Clinical Research in Psychopharmacology and Substance Abuse

    Special issue of the APA journal Experimental and Clinical Psychopharmacology, Vol. 10, No. 3, August 2002. Includes articles about the National Institute on Drug Abuse's clinical research agenda; drug anticipation and the treatment of drug addiction; treatments for pathological gambling; neurocognitive impairment associated with alcohol use disorders; clinical uses of naltrexone; gender differences; and other substance abuse and addiction treatments.

  • The Decade of Behavior

    Special issue of the APA journal Experimental and Clinical Psychopharmacology, Vol. 8, No. 3, August 2000. Includes articles about alcohol and drug abuse research; Pavlovian psychopharmacology; discriminative stimulus effects of benzodiazepines; acquisition of drug self-administration; smoking research; relative reinforcing effects; voucher-based reinforcement therapy; contingency management interventions; achieving long term cocaine abstinence; and drug conditioning in animals.